{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:59:34Z","timestamp":1774310374588,"version":"3.50.1"},"reference-count":77,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title id=\"d624796e24167_w2aab3b7b7b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                  <jats:p>Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title id=\"d624796e24175_w2aab3b7b7b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                  <jats:p>Ancillary data were from the prospective multicenter IVOIRE (hIgh VOlume in Intensive caRE) study. High volume (HV, 70 mL\/kg\/h) was at random compared with standard volume (SV, 35 mL\/kg\/h) CVVH in septic shock patients with acute kidney injury (AKI). PK\/PD parameters for all antimicrobial agents used in each patient were studied during five days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title id=\"d624796e24183_w2aab3b7b7b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                  <jats:p>Antimicrobial treatment met efficacy targets for both percentage of time above the minimal inhibitory concentration and inhibitory quotient. A significant correlation was observed between the ultrafiltration flow and total systemic clearance (Spearman test: <jats:italic>P<\/jats:italic> &lt; 0.005) and between CVVH clearance and drug elimination half-life (Spearman test: <jats:italic>P<\/jats:italic> &lt; 0.005). All agents were easily filtered. Mean sieving coefficient ranged from 38.7% to 96.7%. Mean elimination half-life of all agents was significantly shorter during HV-CVVH (from 1.29 to 28.54 h) than during SV-CVVH (from 1.51 to 33.85 h) (<jats:italic>P<\/jats:italic> &lt; 0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title id=\"d624796e24200_w2aab3b7b7b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                  <jats:p>This study confirms that CVVH influences the PK\/PD behavior of most antimicrobial agents. Antimicrobial elimination was directly correlated with convection rate. Current antimicrobial dose recommendations will expose patients to underdosing and increase the risk for treatment failure and development of resistance. Dose recommendations are proposed for some major antibiotic and antifungal treatments in patients receiving at least 25 mL\/kg\/h CVVH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2478\/jtim-2019-0031","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T09:31:12Z","timestamp":1579339872000},"page":"155-169","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: Lessons learned from an ancillary study of the IVOIRE trial"],"prefix":"10.2478","volume":"7","author":[{"given":"Dominique","family":"Breilh","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacokinetics and Clinical Pharmacy , INSERM U1034 , Haut-L\u00e9v\u00eaque Hospital, CHU Bordeaux , University of Bordeaux , Segalen, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Honore","sequence":"additional","affiliation":[{"name":"Intensive Care Department , Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"De Bels","sequence":"additional","affiliation":[{"name":"Intensive Care Department , Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research , Faculty of Medicine & Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy , The University of Queensland , Brisbane , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Baptiste","family":"Gordien","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacokinetics and Clinical Pharmacy , INSERM U1034 , Haut-L\u00e9v\u00eaque Hospital, CHU Bordeaux , University of Bordeaux , Segalen, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Fleureau","sequence":"additional","affiliation":[{"name":"CHU Bordeaux , Department of Anaesthesia and Critical Care , Magellan Medico-Surgical Centre , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Dewitte","sequence":"additional","affiliation":[{"name":"CHU Bordeaux , Department of Anaesthesia and Critical Care , Magellan Medico-Surgical Centre , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Coquin","sequence":"additional","affiliation":[{"name":"CHU Bordeaux , Department of Anaesthesia and Critical Care , Magellan Medico-Surgical Centre , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadrien","family":"Roz\u00e9","sequence":"additional","affiliation":[{"name":"CHU Bordeaux , Department of Anaesthesia and Critical Care , Magellan Medico-Surgical Centre , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Perez","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Bordeaux , P\u00f4le de Sant\u00e9 Publique, Unit\u00e9 de Soutien M\u00e9thodologique \u00e0 la Recherche Clinique et \u00c9pid\u00e9miologique , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Attou","sequence":"additional","affiliation":[{"name":"Intensive Care Department , Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Redant","sequence":"additional","affiliation":[{"name":"Intensive Care Department , Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Kugener","sequence":"additional","affiliation":[{"name":"Intensive Care Department , Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Saux","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacokinetics and Clinical Pharmacy , INSERM U1034 , Haut-L\u00e9v\u00eaque Hospital, CHU Bordeaux , University of Bordeaux , Segalen, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert D.","family":"Spapen","sequence":"additional","affiliation":[{"name":"Ageing & Pathology Research Group , Vrije Universiteit Brussel , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Ouattara","sequence":"additional","affiliation":[{"name":"CHU Bordeaux , Department of Anaesthesia and Critical Care , Magellan Medico-Surgical Centre , F-33000 Bordeaux , France"},{"name":"Biology of Cardiovascular Diseases, INSERM, UMR 1034 , University of Bordeaux , F-33600 Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Joannes-Boyau","sequence":"additional","affiliation":[{"name":"CHU Bordeaux , Department of Anaesthesia and Critical Care , Magellan Medico-Surgical Centre , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"key":"2023042508114211045_j_jtim-2019-0031_ref_001_w2aab3b7b7b1b6b1ab1b7b1Aa","doi-asserted-by":"crossref","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840\u201351; quiz 859.","DOI":"10.1097\/CCM.0b013e3181961bff"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_002_w2aab3b7b7b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"Fissell WH. Antimicrobial Dosing in Acute Renal Replacement. Adv Chronic Kidney Dis 2013; 20: 85\u201393.","DOI":"10.1053\/j.ackd.2012.10.004"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_003_w2aab3b7b7b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001;45:929\u201334.","DOI":"10.1034\/j.1399-6576.2001.450802.x"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_004_w2aab3b7b7b1b6b1ab1b7b4Aa","doi-asserted-by":"crossref","unstructured":"Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41:1159\u201366","DOI":"10.1086\/444500"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_005_w2aab3b7b7b1b6b1ab1b7b5Aa","doi-asserted-by":"crossref","unstructured":"Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care 2009;13:R57.","DOI":"10.1186\/cc7784"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_006_w2aab3b7b7b1b6b1ab1b7b6Aa","doi-asserted-by":"crossref","unstructured":"Uchino S1, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007;33:1563\u201370.","DOI":"10.1007\/s00134-007-0754-4"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_007_w2aab3b7b7b1b6b1ab1b7b7Aa","doi-asserted-by":"crossref","unstructured":"Cornejo R1, Downey P, Castro R, Romero C, Regueira T, Vega J, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713\u201322.","DOI":"10.1007\/s00134-006-0118-5"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_008_w2aab3b7b7b1b6b1ab1b7b8Aa","doi-asserted-by":"crossref","unstructured":"Joannes-Boyau O, Rapaport S, Bazin R, Fleureau C, Janvier G. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. Asaio J 2004;50:102\u20139.","DOI":"10.1097\/01.MAT.0000104846.27116.EA"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_009_w2aab3b7b7b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581\u20137.","DOI":"10.1097\/00003246-200011000-00001"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_010_w2aab3b7b7b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"Bouman CS, van Kan HJ, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006;32:2013\u20139.","DOI":"10.1007\/s00134-006-0397-x"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_011_w2aab3b7b7b1b6b1ab1b7c11Aa","doi-asserted-by":"crossref","unstructured":"Joannes-Boyau O, Honor\u00e9 PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013;39:1535\u201346.","DOI":"10.1007\/s00134-013-2967-z"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_012_w2aab3b7b7b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, et al. Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. Antimicrob Agents Chemother 2010; 54:2974\u20138.","DOI":"10.1128\/AAC.01582-09"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_013_w2aab3b7b7b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"Toutain J1, Boselli E, Djabarouti S, Allaouchiche B, Xuereb F, Bernadou JM, et al. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:145\u201350.","DOI":"10.1016\/j.jchromb.2004.09.030"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_014_w2aab3b7b7b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"Gordien JB1, Pigneux A, Vigouroux S, Tabrizi R, Accoceberry I, Bernadou JM, et al. Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 2009;50:932\u20138.","DOI":"10.1016\/j.jpba.2009.06.030"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_015_w2aab3b7b7b1b6b1ab1b7c15Aa","doi-asserted-by":"crossref","unstructured":"Gordien JB1, Boselli E, Fleureau C, Allaouchiche B, Janvier G, Lalaude O, et al. Determination of free ertapenem in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006;830:218\u201323.","DOI":"10.1016\/j.jchromb.2005.10.037"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_016_w2aab3b7b7b1b6b1ab1b7c16Aa","unstructured":"FDA. Guidance for industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services Food and Drug Administration 2018 (CDER, CVM). Available from URL at: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Last accessed on December 9, 2019."},{"key":"2023042508114211045_j_jtim-2019-0031_ref_017_w2aab3b7b7b1b6b1ab1b7c17Aa","doi-asserted-by":"crossref","unstructured":"Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007;46:997\u20131038.","DOI":"10.2165\/00003088-200746120-00003"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_018_w2aab3b7b7b1b6b1ab1b7c18Aa","doi-asserted-by":"crossref","unstructured":"Ulldemolins M, Vaquer S, Llaurad\u00f3-Serra M, Pontes C, Calvo G, Soy D, et al. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. Crit Care 2014;18:227","DOI":"10.1186\/cc13938"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_019_w2aab3b7b7b1b6b1ab1b7c19Aa","doi-asserted-by":"crossref","unstructured":"Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, et al. Recommended \u03b2-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011;15:R137.","DOI":"10.1186\/cc10257"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_020_w2aab3b7b7b1b6b1ab1b7c20Aa","doi-asserted-by":"crossref","unstructured":"Taccone FS, de Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011;37:531\u20135.","DOI":"10.1016\/j.ijantimicag.2011.01.026"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_021_w2aab3b7b7b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009;37:2268\u201382.","DOI":"10.1097\/CCM.0b013e3181aab3d0"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_022_w2aab3b7b7b1b6b1ab1b7c22Aa","unstructured":"Golper TA, Marx MA. Drug dosing adjustments during continuous renal replacement therapies. Kidney Int Suppl 1998; 66:S165\u20138."},{"key":"2023042508114211045_j_jtim-2019-0031_ref_023_w2aab3b7b7b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45: 755\u201373.","DOI":"10.2165\/00003088-200645080-00001"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_024_w2aab3b7b7b1b6b1ab1b7c24Aa","doi-asserted-by":"crossref","unstructured":"Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient\u2019s bedside. Pharmacotherapy 2001; 21:319S\u201330S.","DOI":"10.1592\/phco.21.18.319S.33904"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_025_w2aab3b7b7b1b6b1ab1b7c25Aa","doi-asserted-by":"crossref","unstructured":"Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002;46:1557\u201360.","DOI":"10.1128\/AAC.46.5.1557-1560.2002"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_026_w2aab3b7b7b1b6b1ab1b7c26Aa","doi-asserted-by":"crossref","unstructured":"Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA. Pharmacokinetics of piperacillin and tazobactam in plasma and sub-cutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 2014, 43:343\u20138.","DOI":"10.1016\/j.ijantimicag.2014.01.009"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_027_w2aab3b7b7b1b6b1ab1b7c27Aa","doi-asserted-by":"crossref","unstructured":"Awissi DK, Beauchamp A, H\u00e9bert E, Lavigne V, Munoz DL, Lebrun G, et al. Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. Pharmacotherapy 2015;35:600\u20137.","DOI":"10.1002\/phar.1604"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_028_w2aab3b7b7b1b6b1ab1b7c28Aa","doi-asserted-by":"crossref","unstructured":"Yusuf E, Spapen HD, Pi\u00e9rard D. Prolonged vs intermittent infusion of piperacillin\/tazobactam in critically ill patients: a narrative and systematic review. J Crit Care. 2014;29:1089\u201395.","DOI":"10.1016\/j.jcrc.2014.07.033"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_029_w2aab3b7b7b1b6b1ab1b7c29Aa","doi-asserted-by":"crossref","unstructured":"As\u00edn-Prieto E, Rodr\u00edguez-Gasc\u00f3n A, Troc\u00f3niz IF, Soraluce A, Maynar J, S\u00e1nchez-Izquierdo J\u00c1, et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic\/pharmacodynamic analysis. J Antimicrob Chemother 2014;69:180\u20139.","DOI":"10.1093\/jac\/dkt304"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_030_w2aab3b7b7b1b6b1ab1b7c30Aa","doi-asserted-by":"crossref","unstructured":"Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005;49:2421\u20138.","DOI":"10.1128\/AAC.49.6.2421-2428.2005"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_031_w2aab3b7b7b1b6b1ab1b7c31Aa","doi-asserted-by":"crossref","unstructured":"Cotton A, Franklin BD, Brett S, Holmes A. Using imipenem and cilastatin during continuous renal replacement therapy. Pharm World Sci 2005;27:371\u20135.","DOI":"10.1007\/s11096-005-1636-x"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_032_w2aab3b7b7b1b6b1ab1b7c32Aa","doi-asserted-by":"crossref","unstructured":"Mistry GC, Majumdar AK, Swan S, Sica D, Fisher A, Xu Y, et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J Clin Pharmacol 2006;46:1128\u201338.","DOI":"10.1177\/0091270006291839"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_033_w2aab3b7b7b1b6b1ab1b7c33Aa","doi-asserted-by":"crossref","unstructured":"Hidaka S, Goto K, Hagiwara S, Iwasaka H, Noguchi T. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi;130:87\u201394.","DOI":"10.1248\/yakushi.130.87"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_034_w2aab3b7b7b1b6b1ab1b7c34Aa","doi-asserted-by":"crossref","unstructured":"Cirillo I, Vaccaro N, Balis D, Redman R, Matzke GR. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. Antimicrob Agents Chemother 2011;55:1187\u201393.","DOI":"10.1128\/AAC.01063-10"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_035_w2aab3b7b7b1b6b1ab1b7c35Aa","doi-asserted-by":"crossref","unstructured":"Isla A, Rodr\u00edguez-Gasc\u00f3n A, Troc\u00f3niz IF, Bueno L, Solin\u00eds MA, Maynar J, et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 2008;47:173\u201380.","DOI":"10.2165\/00003088-200847030-00003"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_036_w2aab3b7b7b1b6b1ab1b7c36Aa","doi-asserted-by":"crossref","unstructured":"Meyer B, Kornek GV, Nikfardjam M, Karth GD, Heinz G, Locker GJ, Jaeger W, et al. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005;56:172\u20139.","DOI":"10.1093\/jac\/dki133"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_037_w2aab3b7b7b1b6b1ab1b7c37Aa","doi-asserted-by":"crossref","unstructured":"Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, et al. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. AmJ Kidney Dis 2004;44:1097\u2013102.","DOI":"10.1053\/j.ajkd.2004.08.032"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_038_w2aab3b7b7b1b6b1ab1b7c38Aa","doi-asserted-by":"crossref","unstructured":"Roux AF, Moirot E, Delhotal B, Leroy JA, Bonmarchand GP, Humbert G, et al. Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study. Clin Pharmacol Ther 1984;36:363\u20138.","DOI":"10.1038\/clpt.1984.188"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_039_w2aab3b7b7b1b6b1ab1b7c39Aa","unstructured":"Kreeft JH, Ogilvie RI, Dufresne LR. Metronidazole kinetics in dialysis patients. Surgery 1983;93:149\u201353."},{"key":"2023042508114211045_j_jtim-2019-0031_ref_040_w2aab3b7b7b1b6b1ab1b7c40Aa","doi-asserted-by":"crossref","unstructured":"Fuhrmann V, Schenk P, Mittermayer C, El Menyawi I, Ratheiser K, Thalhammer F. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients. Am J Kidney Dis 2003;42:310\u20134.","DOI":"10.1016\/S0272-6386(03)00656-5"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_041_w2aab3b7b7b1b6b1ab1b7c41Aa","doi-asserted-by":"crossref","unstructured":"Choi G, Gomersall CD, Lipman J, Wong A, Joynt GM, Leung P, et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int J Antimicrob Agents 2004;24:468\u201372.","DOI":"10.1016\/S0924-8579(04)00242-0"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_042_w2aab3b7b7b1b6b1ab1b7c42Aa","doi-asserted-by":"crossref","unstructured":"Ronco C, Crepaldi C, Brendolan A, Bordoni V, D\u2019Intini V, Bellomo R. Performance of DIAPES filters in CRRT. Contrib Nephrol 2003;138:144\u201352.","DOI":"10.1159\/000067402"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_043_w2aab3b7b7b1b6b1ab1b7c43Aa","doi-asserted-by":"crossref","unstructured":"Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10\u201327","DOI":"10.2165\/00003088-199324010-00002"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_044_w2aab3b7b7b1b6b1ab1b7c44Aa","doi-asserted-by":"crossref","unstructured":"Berl T, Wilner KD, Gardner M, Hansen RA, Farmer B, Baris BA, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995; 6:242\u2013247","DOI":"10.1681\/ASN.V62242"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_045_w2aab3b7b7b1b6b1ab1b7c45Aa","doi-asserted-by":"crossref","unstructured":"Pittrow L, Penk A. Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycoses 1999;42:17\u20139.","DOI":"10.1046\/j.1439-0507.1999.00269.x"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_046_w2aab3b7b7b1b6b1ab1b7c46Aa","doi-asserted-by":"crossref","unstructured":"Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003;29:1844\u20138.","DOI":"10.1007\/s00134-003-1980-z"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_047_w2aab3b7b7b1b6b1ab1b7c47Aa","doi-asserted-by":"crossref","unstructured":"Bergner R, Hoffmann M, Riedel KD, Mikus G, Henrich DM, Haefeli WE, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019\u201323.","DOI":"10.1093\/ndt\/gfi284"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_048_w2aab3b7b7b1b6b1ab1b7c48Aa","doi-asserted-by":"crossref","unstructured":"Scholz J, Schulz M, Steinfath M, H\u00f6ver S, Bause H. Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med (Berl) 1995;73:145\u20137.","DOI":"10.1007\/BF00198243"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_049_w2aab3b7b7b1b6b1ab1b7c49Aa","doi-asserted-by":"crossref","unstructured":"See comment in PubMed Commons belowMuhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000;56:671\u20138.","DOI":"10.1007\/s002280000216"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_050_w2aab3b7b7b1b6b1ab1b7c50Aa","doi-asserted-by":"crossref","unstructured":"Watt KM, Gonzalez D, Benjamin DK Jr, Brouwer KL, Wade KC, Capparelli E, et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother 2015;59:3935\u201343.","DOI":"10.1128\/AAC.00102-15"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_051_w2aab3b7b7b1b6b1ab1b7c51Aa","doi-asserted-by":"crossref","unstructured":"Kroh UF, Lennartz H, Edwards D, Stoeckel K. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 1996;36:1114\u20139.","DOI":"10.1002\/j.1552-4604.1996.tb04164.x"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_052_w2aab3b7b7b1b6b1ab1b7c52Aa","doi-asserted-by":"crossref","unstructured":"Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000;20:635\u201343.","DOI":"10.1592\/phco.20.7.635.35170"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_053_w2aab3b7b7b1b6b1ab1b7c53Aa","doi-asserted-by":"crossref","unstructured":"Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, et al. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin PharmacokinetSee comment in PubMed Commons below 2006;45:493\u2013501.","DOI":"10.2165\/00003088-200645050-00004"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_054_w2aab3b7b7b1b6b1ab1b7c54Aa","doi-asserted-by":"crossref","unstructured":"Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother. 1984;25:438\u201342.","DOI":"10.1128\/AAC.25.4.438"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_055_w2aab3b7b7b1b6b1ab1b7c55Aa","doi-asserted-by":"crossref","unstructured":"Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, et al. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transplant 2010;25:1279\u201384.","DOI":"10.1093\/ndt\/gfp655"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_056_w2aab3b7b7b1b6b1ab1b7c56Aa","doi-asserted-by":"crossref","unstructured":"Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006;24:548\u201354.","DOI":"10.1159\/000097078"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_057_w2aab3b7b7b1b6b1ab1b7c57Aa","doi-asserted-by":"crossref","unstructured":"Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy 2013;59:143\u201351.","DOI":"10.1159\/000353400"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_058_w2aab3b7b7b1b6b1ab1b7c58Aa","unstructured":"Voriconazole package insert. In. New York, NY: Pfizer Pharmaceuticals, distributed by Roerig Division of Pfizer Inc; 2007 November."},{"key":"2023042508114211045_j_jtim-2019-0031_ref_059_w2aab3b7b7b1b6b1ab1b7c59Aa","doi-asserted-by":"crossref","unstructured":"Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, et al. Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care 2015;19:32.","DOI":"10.1186\/s13054-015-0753-8"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_060_w2aab3b7b7b1b6b1ab1b7c60Aa","doi-asserted-by":"crossref","unstructured":"Quintard H, Papy E, Massias L, Lasocki S, Arnaud P, Desmonts JM, et al. The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient. Ther Drug Monit 2008;30:117\u20139.","DOI":"10.1097\/FTD.0b013e31815c1672"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_061_w2aab3b7b7b1b6b1ab1b7c61Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD. Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident? Crit Care 2015;19:234","DOI":"10.1186\/s13054-015-0946-1"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_062_w2aab3b7b7b1b6b1ab1b7c62Aa","doi-asserted-by":"crossref","unstructured":"von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006;6:6.","DOI":"10.1186\/1472-6904-6-6"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_063_w2aab3b7b7b1b6b1ab1b7c63Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jacobs R, Hendrickx I, Bagshaw SM, Joannes-Boyau O, Boer W, et al. Prevention and treatment of sepsis-induced acute kidney injury: an update. Ann Intensive Care 2015;5:51.","DOI":"10.1186\/s13613-015-0095-3"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_064_w2aab3b7b7b1b6b1ab1b7c64Aa","doi-asserted-by":"crossref","unstructured":"Honor\u00e9 PM, Jacobs R, Joannes-Boyau O, Lochy S, Boer W, De Waele E, et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 2014;37:291\u20135.","DOI":"10.1159\/000363495"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_065_w2aab3b7b7b1b6b1ab1b7c65Aa","doi-asserted-by":"crossref","unstructured":"Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis 2015;82:92\u2013103.","DOI":"10.1016\/j.diagmicrobio.2015.01.013"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_066_w2aab3b7b7b1b6b1ab1b7c66Aa","doi-asserted-by":"crossref","unstructured":"Honor\u00e9 PM, Jacobs R, Joannes-Boyau O, Boer W, De Waele E, Van Gorp V, et al. Continuous renal replacement therapy allows higher colistin dosing without increasing toxicity. J Transl Intern Med 2013;1:6\u20138.","DOI":"10.1515\/jtim-2013-0003"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_067_w2aab3b7b7b1b6b1ab1b7c67Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al. Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J 2013;59:99\u2013106.","DOI":"10.1097\/MAT.0b013e3182816a75"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_068_w2aab3b7b7b1b6b1ab1b7c68Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Spapen HD. Neutrophil gelatinase-associated lipocalin elimination by renal replacement therapy: minding the membrane ! Crit Care 2016;20:87","DOI":"10.1186\/s13054-016-1258-9"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_069_w2aab3b7b7b1b6b1ab1b7c69Aa","doi-asserted-by":"crossref","unstructured":"de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen. Intensive Care Med. 2014;40:998\u20131005.","DOI":"10.1007\/s00134-014-3276-x"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_070_w2aab3b7b7b1b6b1ab1b7c70Aa","doi-asserted-by":"crossref","unstructured":"Beumier M, Roberts JA, Kabtouri H, Hites M, Cotton F, Wolff F, et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 2013;68:2859\u201365.","DOI":"10.1093\/jac\/dkt261"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_071_w2aab3b7b7b1b6b1ab1b7c71Aa","doi-asserted-by":"crossref","unstructured":"Honor\u00e9 PM, Jacobs R, Joannes-Boyau O, Lochy S, Boer W, De Waele E, et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 2014;37:291\u20135.","DOI":"10.1159\/000363495"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_072_w2aab3b7b7b1b6b1ab1b7c72Aa","doi-asserted-by":"crossref","unstructured":"Brasseur A, Hites M, Roisin S, Cotton F, Vincent JL, De Backer D, et al. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother 2016;71:1386\u201394.","DOI":"10.1093\/jac\/dkv491"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_073_w2aab3b7b7b1b6b1ab1b7c73Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD. Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge. Crit Care 2015;19:263.","DOI":"10.1186\/s13054-015-0953-2"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_074_w2aab3b7b7b1b6b1ab1b7c74Aa","doi-asserted-by":"crossref","unstructured":"Boselli E, Breilh D, Rimmel\u00e9 T, Guillaume C, Xuereb F, Saux MC, et al. Alveolar concentrations of piperacillin\/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med. 2008;36:1500\u20136.","DOI":"10.1097\/CCM.0b013e318170ba21"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_075_w2aab3b7b7b1b6b1ab1b7c75Aa","doi-asserted-by":"crossref","unstructured":"Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:4939\u201341.","DOI":"10.1128\/AAC.00441-10"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_076_w2aab3b7b7b1b6b1ab1b7c76Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jacobs R, Lochy S, De Waele E, Van Gorp V, De Regt J, et al. Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorp tion elimination during continuous veno venous hemofiltration. Int J Nephrol Renovasc Dis 2013;6:107\u201311.","DOI":"10.2147\/IJNRD.S42791"},{"key":"2023042508114211045_j_jtim-2019-0031_ref_077_w2aab3b7b7b1b6b1ab1b7c77Aa","doi-asserted-by":"crossref","unstructured":"Honore PM, Jacobs R, Waele ED, Gorp VV, Spapen HD. Colistin pharmacokinetics\/pharmacodynamics and acute kidney injury: A difficult but reasonable marriage. Indian J Crit Care Med 2014;18:415\u20136.","DOI":"10.4103\/0972-5229.136065"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jtim\/7\/4\/article-p155.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2019-0031\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2019-0031\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T08:28:46Z","timestamp":1682411326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2019-0031\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12,31]]},"published-print":{"date-parts":[[2019,12,1]]}},"alternative-id":["10.2478\/jtim-2019-0031"],"URL":"https:\/\/doi.org\/10.2478\/jtim-2019-0031","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}